11 October 2021
BEXIMCO PHARMACEUTICALS LTD.
Update on the supply of COVID-19 vaccine
Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, provides an update on the supply of COVID-19 vaccine in Bangladesh.
As part of the previously announced agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Private Limited (SII), the Company has now received a one-off delivery of one million COVID-19 vaccine doses from SII for distribution in Bangladesh. This is the first delivery since Indian Government controls on vaccine exports began in April. Eight million doses have now been delivered to Bangladesh. Under the terms of the original agreement, 30 million doses are to be delivered in total.
The Company is yet to receive a schedule for delivery of the remaining doses and the Company notes that the Indian Government's policy on vaccine export controls remain unclear at this time.
A further announcement will be made as appropriate.
For further information please visit www.beximcopharma.com or enquire to:
| Beximco Pharma |
| Nazmul Hassan MP, Managing Director Tel: +880 2 58611001, ext.20080
|
| S M Rabbur Reza, Chief Operating Officer Tel: +880 2 58611001, ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, ext.20030
|
| SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
| SP Angel Corporate Finance LLP (Broker) Vadim Alexandre / Abigail Wayne Tel: +44 (0) 20 3470 0470
|
| FTI Consulting Simon Conway / Victoria Foster Mitchell / Sam Purewal Tel: +44 (0)20 3727 1000
|
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.